NasdaqCM - Nasdaq Real Time Price USD

TRxADE HEALTH, Inc. (MEDS)

6.20 -0.01 (-0.16%)
As of 11:22 AM EDT. Market Open.
Loading Chart for MEDS
DELL
  • Previous Close 6.21
  • Open 6.28
  • Bid --
  • Ask --
  • Day's Range 5.93 - 6.42
  • 52 Week Range 3.69 - 44.56
  • Volume 4,358
  • Avg. Volume 438,408
  • Market Cap (intraday) 8.719M
  • Beta (5Y Monthly) 1.93
  • PE Ratio (TTM) --
  • EPS (TTM) -17.96
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Mar 25, 2024
  • 1y Target Est --

TRxADE HEALTH, Inc. operates as a health services information technology (IT) company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement; and designs, develops, owns, and operates a business-to-business web-based marketplace. It also distributes prescription medication, medical devices, and over the counter medication to pharmacies and medical clinics; and offers pricing transparency, purchasing capabilities, and other value-added services, as well as telehealth services. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. was founded in 2010 and is headquartered in Lutz, Florida.

www.trxadehealth.com

8

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MEDS

Trxade health, Inc files its 3Q 10Q

Trxade health, Inc files its 3Q 10Q

Performance Overview: MEDS

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MEDS
78.72%
S&P 500
6.87%

1-Year Return

MEDS
87.61%
S&P 500
25.20%

3-Year Return

MEDS
86.88%
S&P 500
21.95%

5-Year Return

MEDS
51.00%
S&P 500
74.21%

Compare To: MEDS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MEDS

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    8.80M

  • Enterprise Value

    15.76M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.80

  • Price/Book (mrq)

    16.23

  • Enterprise Value/Revenue

    1.90

  • Enterprise Value/EBITDA

    -1.37

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -215.71%

  • Return on Assets (ttm)

    -55.90%

  • Return on Equity (ttm)

    -3,099.92%

  • Revenue (ttm)

    8.27M

  • Net Income Avi to Common (ttm)

    -13.72M

  • Diluted EPS (ttm)

    -17.96

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    151.91k

  • Total Debt/Equity (mrq)

    1,309.83%

  • Levered Free Cash Flow (ttm)

    -2.19M

Research Analysis: MEDS

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: MEDS

Fair Value

6.20 Current
 

Dividend Score

0 Low
MEDS
Sector Avg.
100 High
 

Hiring Score

0 Low
MEDS
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
MEDS
Sector Avg.
100 High
 

People Also Watch